Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL116 Injection in Healthy Volunteers and IgA Nephropathy Patients
CTR20260264Phase 2Active
- Sponsor
- Mabworks Biotech
- Start
- Feb 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CLYM116 in IgA nephropathy (IgAN), sponsored by Mabworks Biotech. Started Feb 2026; status: active.
02
Drugs
CLYM116
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260264.